Anthill Technologies Announces Agreement With Zafgen
Published: Aug 26, 2008
WOBURN, Mass., Aug. 25 /PRNewswire/ -- Anthill Technologies, Inc. today announced that it has entered into an agreement with Zafgen, Inc. to apply its high-speed chemistry technologies and capabilities to Zafgen's obesity program. Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.
Under the agreement, Anthill will use its ACOS(TM) high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs. "We are very pleased to have the opportunity to assist Zafgen in its efforts to find novel and effective therapies to combat obesity," said Dr. Joseph C. Hogan Jr., CEO of Anthill Technologies. "We fully expect that our high-speed chemistry expertise and unique capabilities will help Zafgen to accelerate its obesity therapy discovery program."
Anthill Technologies, Inc. is pioneering the development and commercialization of high-speed chemistry technologies and systems for application across the chemical industry. Founded in 2005, the Company has developed and applied the first in a continuing series of high-speed chemistry systems, known as Applied Chemistry Operating Systems, or ACOS(TM), which are designed to dramatically reduce the time, cost and risks associated with discovering and developing chemical compositions, processes and products for both industrial and pharmaceutical applications. Additional information about Anthill Technologies is available on the Company's website at http://www.anthilltechnologies.com.
CONTACT: Anthill Technologies, Inc., +1-781-937-5558, fax, +1-781-973-4223
Web site: http://www.anthilltechnologies.com/